0.535
전일 마감가:
$0.5362
열려 있는:
$0.5362
하루 거래량:
6.66M
Relative Volume:
1.01
시가총액:
$126.46M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.7133
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-8.08%
1개월 성능:
+13.13%
6개월 성능:
-52.65%
1년 성능:
+67.14%
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
SGMO
Sangamo Therapeutics Inc
|
0.535 | 126.46M | 52.29M | -134.84M | -117.11M | -0.75 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-13 | 업그레이드 | Truist | Hold → Buy |
2024-12-10 | 재확인 | H.C. Wainwright | Buy |
2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
2022-06-13 | 재개 | Wedbush | Neutral |
2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
2021-01-07 | 재개 | Guggenheim | Neutral |
2021-01-06 | 개시 | Stifel | Hold |
2020-12-16 | 재개 | H.C. Wainwright | Buy |
2020-09-08 | 개시 | BofA Securities | Buy |
2020-07-07 | 개시 | SunTrust | Buy |
2019-08-26 | 개시 | H.C. Wainwright | Buy |
2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
2018-10-10 | 개시 | Guggenheim | Buy |
2018-06-20 | 개시 | BofA/Merrill | Buy |
2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2017-06-22 | 재개 | Jefferies | Buy |
2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
2015-12-04 | 개시 | Wells Fargo | Outperform |
2015-10-23 | 재개 | Jefferies | Buy |
2013-05-03 | 개시 | BioLogic Equity Research | Sell |
2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
2010-07-29 | 재확인 | Wedbush | Outperform |
2009-10-19 | 개시 | Brean Murray | Sell |
2009-10-07 | 재확인 | Leerink Swann | Outperform |
2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
Sangamo Biosciences Approves Amendments to Equity Plan - TipRanks
Treg Cell-Based Therapies Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeut - The Globe and Mail
Certain Warrants of Sangamo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2025. - MarketScreener
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
Two Sigma Investments LP Acquires 698,296 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com
Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World
Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock News - GuruFocus
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Sangamo Therapeutics prices $23M securities offering - MSN
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below - GuruFocus
Sangamo Therapeutics (SGMO) Q1 Earnings Miss Expectations - GuruFocus
Jefferies cuts Sangamo BioSciences target to $1.50, keeps Buy - Investing.com
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day - BioSpace
Sangamo Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Sangamo Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
Transcript : Sangamo Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call - Investing.com Nigeria
Sangamo Therapeutics Reports Recent Business Highlights and Firs - GuruFocus
Sangamo Therapeutics (SGMO) Reports First Quarter Revenue Below Expectations | SGMO Stock News - GuruFocus
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwri - GuruFocus
Sangamo Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sangamo Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SGMO) - Seeking Alpha
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results | SGMO Stock News - GuruFocus
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results - BioSpace
Sangamo: Q1 Earnings Snapshot - San Antonio Express-News
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call - Zenopa
Sangamo Therapeutics (SGMO) Anticipates Q1 Earnings Release - GuruFocus
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):